LEXINGTON, Ky. (Oct. 9, 2025) — A team of researchers at the University of Kentucky Sanders-Brown Center on Aging now have a better understanding of how the brain’s support cells communicate with blood vessels — a process that goes awry in Alzheimer’s disease.
LEXINGTON, Ky. (Oct. 1, 2025) — University of Kentucky scientists received $1.8 million through the National Institutes of Health (NIH) East Palestine, Ohio, Train Derailment Health Research Program to conduct critical research into the long-term health effects of the 2023 disaster. The funding — from NIH’s National Institute of Environmental Health Sciences (NIEHS) — supports the program’s first year of work, and the university will be a major contributor by helping to lead a consortium of three academic institutions. The program is administered by NIEHS and the National Center for Advancing Translational Sciences, also part of NIH.
LEXINGTON, Ky. (Sept. 22, 2025) — Breakthroughs in neuroscience are happening at the University of Kentucky’s Spinal Cord and Brain Injury Research Center (SCoBIRC), where researchers are working to turn discovery into new therapies for people living with spinal cord and brain injuries.
LEXINGTON, Ky. (Sept. 11, 2025) — As Kentucky’s flagship, land-grant institution, the University of Kentucky is charged with finding solutions to meet the needs of the Commonwealth.
LEXINGTON, Ky. (Aug. 27, 2025) — University of Kentucky Markey Cancer Center researchers have identified a cellular pathway that fuels the progression of aggressive, drug-resistant prostate cancer. The findings of the study, published in the Journal of Clinical Investigation, could lead to new treatment approaches for patients whose cancers no longer respond to hormone therapy.
LEXINGTON, Ky. (July 29, 2025) – University of Kentucky Markey Cancer Center researchers have identified a protein that could be a promising treatment target for obesity-related breast cancer.
LEXINGTON, Ky. (July 25, 2025) —University of Kentucky Markey Cancer Centerresearchers have discovered a genetic biomarker that could help identify patients with glioblastoma most likely to benefit from the cancer drug bevacizumab. The study, published in JCO Precision Oncology, found that brain tumors from patients treated with bevacizumab who lived longer were more likely to have a genetic change called CDK4 amplification. This suggests that testing for the molecular marker could help oncologists identify patients most likely to respond well to bevacizumab treatment.
LEXINGTON, Ky. (July 11, 2025) — University of Kentucky Markey Cancer Centerresearcher Weisi Yan, M.D., Ph.D., recently shared his work on radiation therapy at a major international conference, showcasing how new techniques could better protect patients’ immune systems while fighting cancer.
LEXINGTON, Ky. (June 30, 2025) — It’s a frightening statistic: someone in the U.S. has a heart attack every 40 seconds. For many Kentuckians, the risk is even higher due to widespread health challenges like obesity, smoking and chronic illness.
Jason Unrine, Ph.D., is supported by the National Institute of Environmental Health Sciences (NIEHS), which leads research on how the environment affects biological systems across the lifespan. The ultimate goal is to reduce disease and promote human health.
